Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 154 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: apixaban Clear all
Completed Phase 2 Interventional Results available

Safety Study of Apixaban in Recent Acute Coronary Syndrome

NCT00313300
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

NCT02034591
View directory record Official record
Conditions
Healthy Subjects
Interventions
Apixaban, Boost Plus
Drug · Dietary Supplement
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Apixaban, No systemic anticoagulant prophylaxis
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 21, 2026, 9:13 AM EDT
Terminated Not applicable Interventional Results available

Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

NCT03465735
View directory record Official record
Conditions
Acute DVT of Lower Extremity
Interventions
Vascular Boot, Standard of Care
Combination Product · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

NCT03310021
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 21, 2026, 9:13 AM EDT
Recruiting Phase 2 Interventional

Venous Thromboembolism Prevention in Outpatients With Glioma

NCT05683808
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 21, 2026, 9:13 AM EDT
Terminated Phase 3 Interventional Results available

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

NCT03192215
View directory record Official record
Conditions
Stroke
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
165
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

NCT01340586
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Phase 2 Interventional Results available

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

NCT02366871
View directory record Official record
Conditions
Gynecologic Cancer, Venous Thromboembolism
Interventions
Oral apixaban, Subcutaneous enoxaparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 21, 2026, 9:13 AM EDT
Withdrawn Phase 2 Interventional

Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study

NCT02450682
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 21, 2026, 9:13 AM EDT
Completed No phase listed Observational

Apixaban Discontinuation Prior to Major Surgery

NCT02935751
View directory record Official record
Conditions
Hemorrhage, Thromboembolism
Interventions
Lab tests for plasma levels of apixaban and anti-10a factor
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 99 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 21, 2026, 9:13 AM EDT
Recruiting No phase listed Observational

Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™

NCT07012291
View directory record Official record
Conditions
Coagulation
Interventions
Whole Blood Clotting Time
Device
Lead sponsor
Perosphere Technologies Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Danbury, Connecticut • Rockville, Maryland • Denville, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 21, 2026, 9:13 AM EDT
Active, not recruiting Not applicable Interventional

The PEERLESS II Study

NCT06055920
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Phase 4 Interventional Results available

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

NCT02090075
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
apixaban, warfarin
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Phase 4 Interventional

Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy

NCT02227550
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Vitamin K antagonist, Apixaban
Drug
Lead sponsor
Atrial Fibrillation Network
Other
Eligibility
18 Years and older
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

NCT00320255
View directory record Official record
Conditions
Thrombosis, Cancer, Pulmonary Embolism
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 21, 2026, 9:13 AM EDT
Completed No phase listed Observational

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

NCT04394234
View directory record Official record
Conditions
Uterine Hemorrhage
Interventions
Direct oral anticoagulant (DOACs), Warfarin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
961,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 21, 2026, 9:13 AM EDT
Not yet recruiting Phase 3 Interventional

Restarting Anticoagulation After Traumatic Intracranial Hemorrhage

NCT04229758
View directory record Official record
Conditions
Hemorrhage, Intracranial Hemorrhages, Bleeding, Trauma
Interventions
Anticoagulants
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 21, 2026, 9:13 AM EDT
Terminated Phase 3 Interventional Results available

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

NCT03839355
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 21, 2026, 9:13 AM EDT
Completed No phase listed Observational

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

NCT03521908
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

NCT03083704
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 21, 2026, 9:13 AM EDT
Completed No phase listed Observational

Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients

NCT01727427
View directory record Official record
Conditions
Unsuspected Pulmonary Embolism
Interventions
Heparin, fondaparinux, vitamin-K antagonists, aspirin
Drug
Lead sponsor
G. d'Annunzio University
Other
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 21, 2026, 9:13 AM EDT
Completed No phase listed Observational

Apixaban Validation Study - Additional Study on Fresh Samples

NCT03073265
View directory record Official record
Conditions
Anticoagulation With Apixaban
Interventions
STA-Apixaban Calibrator & Control
Device
Lead sponsor
Diagnostica Stago
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Greensboro, North Carolina • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 21, 2026, 9:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation

NCT01578044
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Intervention, Control
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 21, 2026, 9:13 AM EDT